Arikayce Liposomal: Non-tuberculous Mycobacteria
(asked on 13th October 2022) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether Arikayce liposomal will be made available on the NHS for patients with non-tuberculosis mycobacteria; and if she will make a statement.
This question was answered on 24th October 2022
NHS England is concluding a prioritisation process which will determine whether Arikayce (nebulised amikacin) treatment for patients with non-tuberculous mycobacteria will be made available. Further information will be available in due course.